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Abstract 
Background 
Patients’ knowledge regarding their oral anticoagulant (OAC) treatment for stroke prevention in 
atrial fibrillation (AF), their level of medication adherence and health literacy are known to affect 
treatment outcomes. However, contemporary data regarding the relationships between these 
variables are lacking. 
Objective 
To investigate the relationships between anticoagulant knowledge, health literacy and self-reported 
adherence in patients taking warfarin and the directly acting oral anticoagulants. 
Methods 
A cross-sectional survey was conducted in 48 patients with AF identified from general practices. The 
Anticoagulation Knowledge Tool (AKT) was used to assess anticoagulation knowledge; the Short Test 
of Functional Health Literacy in Adults (s-TOHFLA) for health literacy; and the 8-item Morisky 
Medication Adherence Scale (MMAS) for medication adherence. 
Results 
Participants had mean scores of 61.6 ± 15.8, 7.2 ± 1.1 and 24.7 ± 9.5 for the AKT, MMAS-8 and s-
TOHFLA, respectively. Significant correlations were observed between anticoagulation knowledge 
and health literacy with medication adherence (0.37, p <0.01 and 0.30, p < 0.05, respectively). 
Participants with inadequate health literacy had a significantly lower mean knowledge score than 
those with adequate health literacy (55.8 ± 15.9 vs 66.1 ± 14.4, p <0.05). Participants who self-
reported adherence to their OAC had significantly higher knowledge scores than those who did not 
(67.5 ± 13.3 vs 56.1 ± 16.2, p < 0.05).  
Conclusion 
Significant correlations between health literacy, OAC knowledge and adherence were observed, and 
these relationships should to be considered by health professionals responsible for monitoring 
patients who are prescribed anticoagulants. We also observed serious gaps in OAC knowledge. 
Interventions designed to optimize the outcomes of anticoagulant treatment need to address these 
factors. 
 
Introduction 
Atrial fibrillation (AF) is associated with significant morbidity and mortality, and stroke resulting from 
AF presents a large and growing economic concern.1 Anticoagulation therapy in at risk patients with 
AF can markedly reduce stroke risk and is therefore an important component of AF management. 1 
Under-use of OACs in AF is often reported in terms of under-prescribing of treatment, but poor 
treatment outcomes in people with AF also commonly result from poor adherence or persistence 
with anticoagulant therapy even when it is prescribed, often with devastating consequences.2  
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Patients’ oral anticoagulation knowledge, level of medication adherence and health literacy are 
known to affect treatment outcomes. However, contemporary data regarding the relationships 
between these variables are lacking. 
 
Medication adherence in chronic disease is a worldwide problem.  Up to 50% of patients are non-
adherent to medications, including OACs.3-5 Limited health literacy is associated with poor warfarin 
and AF knowledge.6,7 In addition, poor warfarin knowledge and lack of education about warfarin 
have been associated with inadequate anticoagulant control and increased hemorrhagic events, and 
those at highest risk of stroke have been shown to have the poorest knowledge regarding their 
treatment. 6,8,9 It is unknown whether similar results will be seen in patients who take directly acting 
oral anticoagulants (DOACs).  
 
The introduction of the DOACs has sought to address some of the pitfalls of warfarin therapy, 
however there are persisting challenges to overcome; adherence to the drug regimen being the 
most crucial. Due to their short half-lives, irregular or missed doses can increase the risk of stroke, as 
the patient will be inadequately anticoagulated during this time. 10,11 
 
The 2016 European Society of Cardiology (ESC) guidelines for the management of AF recommend an 
integrated approach to care with particular focus on the patient being central to effective 
management. Integral to patient centered care is patient education, which in turn empowers self-
management and shared decision making. As a European Heart Rhythm Association, priority 
research area and acknowledged by the ESC guidelines, more research is needed to determine the 
best way to deliver an integrated approach.1,12 
 
Given the interest in integrated AF care, and the lack of contemporary data investigating the 
relationships between health literacy, adherence behaviors and medication knowledge of patients 
taking OACs for stroke thromboprophylaxis in AF, the aim of this study was to investigate the 
relationships between these variables and to assess the strength of the relationship between 
knowledge and health literacy. 
 
Methods 
Recruitment 
Participants were recruited to the study from participating general practices or outpatient 
cardiologist clinics in Tasmania, Australia. Invitation letters with a response form were sent to the 
practices requesting their participation in the study and asking that patients with AF in their 
practices be given the opportunity to participate in the study. To be eligible to participate, 
participants had to be over 18 years of age, have a diagnosis of non-valvular AF, be currently taking 
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warfarin or DOACs for stroke thromboprophylaxis and be able to provide informed consent.  
Participants were interviewed either at their regular GP surgery or in their home as these were 
considered familiar and comfortable surroundings. A $10 AUD shopping voucher was provided to all 
participants as recruitment incentive and as compensation for their time at the end of the interview.  
 
Data Collection 
The interview consisted of four validated questionnaires - the 8-item Morisky Medication Adherence 
Scale (MMAS-8), Anticoagulant Knowledge Tool (AKT), Short Test of Functional Health Literacy in 
Adults (s-TOFHLA) and the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire, 
presented to participants in this order. Participants were introduced to the study using a script and 
all questionnaires were undertaken in an interview style, with the exception of s-TOHFLA which 
participants completed by themselves within a seven-minute time limit. Each interview took 
between 20 and 45 minutes and all were completed in a single session.  
 
Adherence 
To assess self-reported adherence behavior, we used the MMAS-8 questionnaire, which asks seven 
dichotomous questions and one 5-point Likert scale question.13-15 The validated MMAS-8 was chosen 
as it has been shown to be a reliable predictor of adherence in patients taking medications for 
chronic diseases, such as antihypertensives, and has been used to assess adherence in those taking 
OACs. 14,16,17 In assessing adherence using the MMAS-8, a score of 8 was considered adequate 
adherence, while a score of less than 8 was considered inadequate adherence.16 
 
Knowledge 
To assess the level of knowledge of OAC therapy and its role, including participant 
perceptions/understanding of the risks and benefits, we used the AKT, which was developed to 
assess the anticoagulant knowledge of patients taking either warfarin or DOACs. A score of ‘1’ or ‘0’ 
was given for correct and incorrect answers, respectively. Participants taking a DOAC were required 
to answer only section ‘A’ with a total maximum score of 25 and participants taking warfarin were 
required to answer sections ‘A’ and ‘B’ with a total maximum score of 35. Final scores were 
presented as percentages of correct answers for all participants.18 
 
Health Literacy 
To assess functional health literacy, we used the s-TOFHLA.19 Dichotomous scoring of ‘1’ for correct 
answers and ‘0’ for incorrect answers was used and a maximum score of 36 could be achieved. In 
scoring the s-TOFHLA scale, a score of 23 and above was considered adequate health literacy, while 
a score of 22 and less was considered inadequate health literacy.6,20 
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Quality of Life 
To assess AF specific health related quality of life we used the AFEQT. For AFEQT questions 1-20, 
responses were scored on a 1 to 7 Likert scale. An overall score of 0-100 could be achieved, 
corresponding to ‘complete disability’ to ‘no disability’, respectively. AFEQT was chosen as it 
combines the scores from four parameters: symptoms, daily activities, treatment concerns and 
satisfaction to a single measure with reliability, and has focused questions surrounding the use of 
anticoagulants.21,22  
 
Statistical Analysis 
Statistical analysis was performed using SPSS version 24 (IBM, Armonk, New York, US).  
Means and standard deviations were used to summarize continuous variables, and independent 
sample t-tests were used for inferential statistics. s-TOFHLA and MMAS-8 scores were analyzed as 
both continuous and dichotomous variables. Correlations between AKT, s-TOFHLA and MMAS-8 
scores were determined using the Spearman rank coefficient. Logistic regression analysis was used 
to estimate regression coefficients for AKT and s-TOFHLA against MMAS-8 adherence scores in both 
univariate and multivariate models. A p value of <0.05 was considered statistically significant for all 
analyses. 
 
Sample size 
Using a 5% margin of error and statistical power of 80%, we determined that a sample size of 40 
participants would be sufficient to detect a moderate statistical correlation  of 0.4 between the AKT 
score and s-TOFHLA score with the MMAS-8 adherence score.  
 
Ethics 
The Tasmanian Health and Medical Human Research Ethics Committee (reference number 
H0015395) approved this study. Informed consent was obtained from all individual participants 
included in the study. 
Results 
Demographic characteristics 
Fifty participants were interviewed. The results of two participants were excluded because they had 
discontinued their OAC at the time of the interview, leaving data from 48 participants available for 
analysis. The average age of the participants was 76.4 ± 8.7 years and the majority (77.1%) were 
male (Table 1). Forty-two percent of participants had either high school education (Year 10 
equivalent) or college (Year 12 equivalent) as the highest level of education completed. The majority 
of the participants were taking a DOAC (64.6%) at the time of the study, and had been taking an 
anticoagulant for greater than 2 years (75.0%).  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Association between level of self-reported adherence and health literacy, knowledge and AF-
related quality of life 
 Adequate adherence to the prescribed OAC was reported by 47.9% of participants and this group 
had a significantly higher total knowledge score than those who were non-adherent (67.5% vs 
56.1%, p = 0.011) (Table 2). However, no association between the level of adherence with health 
literacy and AF-related quality of life was observed. 
Table 1. Demographic characteristics n (%) 
Parameter Overall Sample (n= 48) 
Male  37 (77.1) 
Age in years (mean +/- SD) 76.4 ± 8.7 
Highest education completed n (%) 
High school 14 (29.2) 
College 6 (12.5) 
Technical/ Vocational 13 (27.1) 
Bachelor degree 11 (22.9) 
Post graduate 4 (8.3) 
Duration of anticoagulant therapy n (%) 
Less than 3 months 1 (2.1) 
3-12 months 5 (10.4) 
1-2 years 6 (12.5) 
Greater than 2 years 36 (75.0) 
Oral anticoagulant n (%) 
Warfarin 17 (35.4) 
DOAC 31 (64.6) 
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Level of health literacy and knowledge  
As shown in Table 3, when participants were categorized based on their health literacy scores, those 
with inadequate health literacy had a significantly lower mean total anticoagulant knowledge score 
than those with adequate health literacy (55.8 ± 15.9 versus 66.1 ± 14.4, p = 0.02). Furthermore, 
participants with inadequate health literacy were less likely than those with adequate health literacy 
to know why they had been prescribed an OAC (57.1% versus 85.2%, p = 0.04), less likely to know 
how the medication worked (42.9% versus 88.9%, p = 0.001) and less likely to be able to describe 
one sign of side effects to watch out for whilst taking an anticoagulant (28.6% versus 70.4%, p = 
0.03). In addition, only 16.7% of all participants could mention three signs of side effects to watch 
out for while taking an OAC (Table 3).  
 
 
 
 
 
 
Table 2. Association between adherence level  and study variables 
Parameter Overall 
Sample  
(n= 48) 
Inadequate 
Adherence 
(MMAS-8 Score < 8) 
(n=25) 
Adequate Adherence 
(MMAS-8 score = 8) 
(n=23) 
p value 
Total AKT score 61.6 ± 15.8 56.1 ± 16.2 67.5 ± 13.3 0.011* 
s-TOFHLA  24.7 ± 9.5 22.9 ± 9.9 26.7 ± 8.8 0.171 
Overall AFEQT 80.1 ± 15.8 81.3 ± 16.7 78.8 ± 14.9 0.593 
*p<0.05 
Use of the ©MMAS is protected by US and International copyright laws. Permission for use is 
required. A license agreement is available from: Donald E. Morisky, MMAS Research 
(MORISKY), 14725 NE 20th St Bellevue WA 98007, USA; dmorisky@gmail.com. 
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Table 3. Anticoagulation knowledge score according to health literacy level 
Item 
Overall 
Sample 
(n= 48) 
n (%) 
Inadequate 
Health 
Literacy 
(n=21) 
n (%) 
Adequate 
Health 
Literacy 
(n=27)  
n (%) 
p value 
What is the name of your anticoagulant 
medicine? 
43 (89.6) 17 (81.0) 26 (96.3) 0.119 
Why has your doctor prescribed you this 
medicine? 
35 (72.9) 12 (57.1)  23 (85.2) 0.039* 
How does this medicine work in your body?   33 (68.8) 9 (42.9) 24 (88.9) 0.001* 
How many times a day do you need to take this 
medicine? 
48 (100.0) 21 (100.0) 27 (100.0) NA 
For how long do you need to take this medicine 
(for example, 3 months, and 6 months, life-long)? 
47 (97.9) 20 (95.2) 27 (100.0) 0.329 
Why is it important to take this medicine exactly 
as your doctor has told you? 
 (Stroke) 
28 (58.3) 10 (47.6) 18 (66.7) 0.192 
Why is it important to take this medicine exactly 
as your doctor has told you? 
 (bleeding) 
1 (2.1) 1(4.8) 0 (0.0) 0.329 
Is it important to take this medicine at the same 
time each day? 
42 (87.5) 18 (85.7)  24 (88.9) 0.748 
Is it okay to double the next dose of this medicine 
if you miss a dose? 
46 (95.8) 21 (100.0) 25 (92.6) 0.161 
Is it possible that skipping one dose of this 
medicine could worsen your condition? 
19 (39.6) 7 (33.3) 12 (44.4) 0.446 
Is it appropriate to stop taking this medicine once 
you feel better? 
44 (91.7) 18 (85.7) 26 (96.3) 0.231 
Is it safe to take anti-inflammatory medicines like 
ibuprofen (Nurofen® or Advil®) while you are 
taking this medicine? 
28 (58.3) 15 (71.4) 13 (48.2) 0.105 
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Is it safe to take vitamin supplements and herbal 
medicines with this medicine without consulting 
your doctor?  
30 (62.5) 15 (71.4) 15 (55.6) 0.264 
Is there any benefit in taking more of this 
medicine than your doctor has told you to take?  
44 (91.7) 18 (85.7) 26 (96.3) 0.231 
Will drinking too much alcohol increase the risk 
of side effects with this medicine? 
18 (37.5) 9 (42.9) 9 (33.3) 0.513 
Is it necessary to inform a surgeon, dentist or 
other health professional that you are taking this 
medicine before undergoing surgery or a 
procedure? 
47 (97.9) 20 (95.2) 27 (100.0) 0.329 
Is it important that all the health care practitioners 
you see know that you are taking this medicine? 
47 (97.9) 20 (95.2) 27 (100.0) 0.329 
What is the most important side effect of this 
medicine?  
21 (43.8) 7 (33.3) 14 (51.9) 0.208 
THREE signs of side effects that you should 
watch out for while taking this medicine are: 
(1/3) 
25 (52.1) 6 (28.6) 19 (70.4) 0.003* 
THREE signs of side effects that you should 
watch out for while taking this medicine are: 
(2/3) 
15 (31.3) 5 (23.8) 10 (37.0) 0.337 
THREE signs of side effects that you should 
watch out for while taking this medicine are: 
(3/3) 
8 (16.7) 2 (9.5) 6 (22.2) 0.231 
THREE things you can do to reduce your risk of 
side effects are: (1/3) 
16 (33.3) 4 (19.1) 12 (44.4) 0.059 
THREE things you can do to reduce your risk of 
side effects are: (2/3) 
7 (14.6) 1 (4.8) 6 (22.2) 0.072 
THREE things you can do to reduce your risk of 
side effects are: (3/3) 
6 (12.5) 1 (4.8) 5 (18.5) 0.133 
What is the best step to take if you accidentally 
take too much of this medicine?  
34 (70.8) 16 (76.2) 18 (66.7) 0.482 
Warfarin specific questions 
Item 
Overall 
Sample 
(n=17) 
Inadequate 
Literacy 
(n=9) 
Adequate 
Literacy 
(n=8)  
p value 
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n % n (%) n (%) 
What is your target INR range? 11 (64.7) 5 (55.6) 6 (75.0) 0.431 
What was your last INR reading? 16 (94.1) 8 (88.9) 8 (100.0) 0.347 
Are routine INR tests necessary to know how 
well this medicine is working? 
15 (88.2) 8 (88.9) 7 (87.5)  0.935 
Is an INR value above your target range good for 
your general wellbeing? 
13 (76.5) 6 (66.7) 7 (87.5) 0.334 
Is it possible for INR values below your target 
range to be bad for your health? 
12 (70.6) 5 (55.6) 7 (87.5) 0.161 
Is it possible for what you eat to affect your 
warfarin therapy? 
14 (82.4) 6 (66.7) 8 (100.0) 0.081 
If you answered ‘Yes’ above, list THREE foods 
that can affect your anticoagulant therapy: (1/3) 
12 (70.6) 5 (55.6) 7 (87.5) 0.161 
If you answered ‘Yes’ above, list THREE foods 
that can affect your anticoagulant therapy: (2/3) 
12 (70.6) 5 (55.6) 7 (87.5) 0.161 
If you answered ‘Yes’ above, list THREE foods 
that can affect your anticoagulant therapy: (3/3)  
11 (64.7) 4 (44.4) 7 (87.5) 0.066 
List one vitamin that can significantly affect your 
anticoagulant therapy. 
6 (35.3) 2 (22.2) 4 (50.0) 0.259 
Total AKT score (%) 61.6 ± 15.8 55.8  
± 15.9 
66.1  
± 14.4  
0.022* 
*p<0.05 
 
 
Association between adherence, knowledge and health literacy  
There were moderate positive correlations between the mean scores of self-reported adherence, 
anticoagulant knowledge and health literacy (Figure 1). Multivariate analysis showed that 
anticoagulation knowledge was significantly associated with MMAS-8 score even after adjusting for 
health literacy score (OR, 1.050; 95% CI, 1.003 – 1.100; p = 0.036), Table 4). There were no 
statistically significant relationships between total AF specific health related quality of life scores and 
other study variables.  
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Figure 1 Correlations between study variables  
 
*Correlation is significant at the 0.05 level (2-tailed)  
** Correlation is significant at the 0.01 level (2-tailed) 
 
 
 
 
 
 
 
 
 
 
 
 
MMAS-8 
score 
AKT score 0.309* 
STOFHLA 
score 
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Table 4. Association of knowledge and health literacy scores with MMAS-8 score (logistic 
regression) 
Independent 
variables 
Unadjusted model Adjusted model 
 OR (95%CI) p value OR (95%CI) p value 
Knowledge  
Score 
1.054 (1.009 – 1.101) 0.017* 1.050 (1.003 – 1.100) 0.036* 
Health Literacy 
Score 
1.045 (0.981 – 1.114) 0.171 1.018 (0.948 – 1.092) 0.631 
Model statistics: Nagelkerke R
2 
= 18.1% 
CI, confidence interval; MMAS-8, 8-item Morisky medication adherence scale. 
* p<0.05 
Use of the ©MMAS is protected by US and International copyright laws. Permission for use is 
required. A license agreement is available from: Donald E. Morisky, MMAS Research (MORISKY), 
14725 NE 20th St Bellevue WA 98007, USA; dmorisky@gmail.com. 
 
Discussion 
This study provides valuable data supporting relationships between adherence, OAC knowledge and 
health literacy. Participants who self-reported adherence to their OAC had significantly higher 
knowledge scores than those who did not. In addition, participants with adequate health literacy 
achieved significantly higher knowledge scores. Positive correlations between health literacy, 
knowledge and adherence scores were also observed, suggesting that these concepts are interlinked 
and should be considered when managing patients taking OACs for stroke thromboprophylaxis in AF. 
The Capability, Opportunity and Motivation (COM-B) model of Behavior to increase medication 
adherence provides a dynamic framework in order to identify appropriate interventions that address 
the modifiable factors influencing non-adherence. 23,24 Mapping the results from this study to the 
COM-B framework suggests each of the domains (COM) are involved and need to be addressed in 
order to increase OAC adherence (B).23,24 
 
Poor adherence to OACs is frequently reported in the literature and has been associated with poor 
clinical outcomes. 2,4,5,25,26 In our study, 48% of participants reported adequate adherence to their 
prescribed OAC.  This is similar to the study by Davis et al. in patients taking warfarin, in which only 
50% of participants reported adequate adherence.4 A recent review of adherence and persistence to 
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OACs in AF found that in the studies available, poor adherence is associated with poor treatment 
outcomes such as stroke and bleeding.26 Yao et al. recently undertook a large retrospective cohort 
study in patients taking OACs for stroke prevention in AF and found that those with a high estimated 
stroke risk were at an increased risk of stroke when they were not taking anticoagulation for 6 
months or more (hazard ratio 2.73, p <0.001), clearly indicating that better medication taking 
behavior leads to better outcomes.2 
Taking into consideration the importance of adherence in ensuring a steady plasma concentration 
with DOACs and their lack of routine laboratory monitoring11, our study suggests that patients taking 
DOACs may require routine follow up by health care practitioners (HCPs) to ensure that they adhere 
to their medication. This fit within the COM-B sub-category of Physical Opportunity, which suggests 
that HCP-patient communication and relationships can be improved through routine clinical follow 
up, in turn leading to increased adherence.23,24  
We observed a total mean knowledge score of 62%. This is similar to the result of other studies in 
the literature, where a mean knowledge score of less than 70% has been reported in different 
populations.18,27-29 From the results of our study, participants who were considered adherent had a 
significantly higher mean total knowledge score than those who were non- adherent, and 
knowledge remained significantly associated with adherence even after adjusting for the level of 
health literacy. Forty percent of all participants did not know that taking an OACs as the doctor had 
prescribed reduced the risk of stroke and 60% of all participants did not know that skipping a dose of 
their OAC could worsen their condition. In support of these findings, a recent study by Desteghe et 
al. found that 34% were unaware that AF could cause a stroke and 57% of the patients taking DOACs 
did not know what to do when they miss a dose.29 Lane et al. found that only approximately 50% 
could name their condition and perceived it as a serious condition that could predispose them to a 
stroke.30  Few studies have examined whether poor DOAC knowledge leads to poor clinical 
outcomes, however this has been demonstrated in those taking warfarin.6,8,9 Our study reveals 
specific deficiencies in the knowledge of both warfarin and DOAC-taking participants. In addition, it 
provides a platform to inform the development of educational interventions and justifies the need 
for further research in this area. 
Limited health literacy may be an indicator of deficits in warfarin knowledge.6,7 Fang et al reported 
that 67% of patients taking warfarin for stroke prevention in AF had limited health literacy (s-
TOFHLA score of 0-22) and this group had significantly inadequate disease and medication-related 
knowledge in comparison to those with adequate health literacy.6 These results align well with our 
study, which found that those with inadequate health literacy had a significantly lower mean total 
anticoagulant knowledge score in comparison to those with adequate health literacy. Participants 
with inadequate health literacy were less likely than those with adequate health literacy to know 
why they had been prescribed an OAC, less likely to know how the medication works and less likely 
to be able to describe one sign of side effects to watch out for while taking an anticoagulant. 
Patients need to know what they have been prescribed and why, as well any possible side effects. 
Paucity in patients’ knowledge can have a profound effect on the management of AF.31  
Lack of knowledge and health literacy, comprehension of the disease and treatment, perception of 
illness and beliefs about treatment including concern of side effects and bleeding fits within the 
COM-B sub-categories of Psychological Capability and Reflective Motivation.23,24 It has been 
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suggested that these categories can be addressed by HCPs giving information to patients to shape 
their knowledge, with the intention to enhance a patient’s capability to understand and engage in 
their therapy.23,24 With the goal of improving adherence through patient centered care, 
consideration of health literacy and its association with knowledge and adherence in patients taking 
OACs for stroke prevention in AF should therefore not be overlooked. Adherence may be improved 
through implementation of individually tailored educational interventions focusing on improving the 
disease and medication-related knowledge of the patient.  
Limitations 
There are a number of limitations to this study, including the cross-sectional methodology and small 
sample size. Furthermore, we did not collect information on the quality of education given to 
participants on their OACs upon initiation, nor did we determine if participants who were taking a 
DOAC at the time of the interview had previously been taking warfarin. The limitations of the tools 
used should also be considered. We anecdotally observed that many participants were unable to 
differentiate between the effect of AF and other co-morbidities such as heart failure or older age on 
quality of life. This made it difficult for participants to definitively say that AF was the condition 
causing their symptoms, such as shortness of breath or limiting their ability to exercise. Medication 
adherence was quantified by self-report; this approach can possibly overestimate the level of 
adherence observed.32 
Implications for further research 
Recent clinical guidelines have placed emphasis on integrating the patient and their preferences into 
AF management to improve outcomes.1 The results of this study help to inform the implementation 
of patient centered integrated AF management and reinforce the need for additional research. 
Considering the demonstrated correlation between health literacy, knowledge and adherence, 
larger studies are required to determine if improving these patient centered aspects of OAC 
management in AF leads to improved treatment outcomes. Moreover, this study reveals gaps in the 
knowledge of participants taking OACs. A large prospective study assessing anticoagulant knowledge 
in this population will be useful in identifying specific areas of lacking knowledge to improve OAC 
education.   
 
Conclusion 
In conclusion, the results of this study demonstrate a significant relationship between health 
literacy, OAC knowledge and self-reported adherence behaviours. They also highlight inadequate 
medication adherence behavior and health literacy levels, and gaps in patient oral anticoagulation 
knowledge. To adopt a true patient centered approach to AF management, it is important for HCPs 
to consider these variables in patients taking OACs for stroke prevention in AF. Interventions 
designed to optimize the outcomes of anticoagulant treatment need to address these factors. 
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